

Ziding Feng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10490556/publications.pdf>

Version: 2024-02-01

170
papers

17,995
citations

16411

64
h-index

12910

131
g-index

171
all docs

171
docs citations

171
times ranked

22089
citing authors

#	ARTICLE	IF	CITATIONS
1	Conceptual Model for the Hepatocellular Carcinoma Screening Continuum: Current Status and Research Agenda. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 9-18.	2.4	58
2	Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 451-459.	2.3	13
3	Counting Advanced Precancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1040-1043.	3.0	1
4	Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "cribriform" prostatic adenocarcinoma. <i>Modern Pathology</i> , 2022, 35, 1092-1100.	2.9	10
5	A multivariate parametric empirical Bayes screening approach for early detection of hepatocellular carcinoma using multiple longitudinal biomarkers. <i>Statistics in Medicine</i> , 2022, 41, 2338-2353.	0.8	1
6	Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. <i>Human Pathology</i> , 2022, 122, 84-91.	1.1	6
7	Personalized statistical learning algorithms to improve the early detection of cancer using longitudinal biomarkers. <i>Cancer Biomarkers</i> , 2022, 33, 199-210.	0.8	0
8	The COMPASS study: A prospective, randomized, multi-center trial testing the impact of a clinic-based intervention informing patients of colorectal cancer screening options on screening completion. <i>Contemporary Clinical Trials</i> , 2022, 119, 106852.	0.8	0
9	Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules. <i>Journal of Thoracic Oncology</i> , 2021, 16, 228-236.	0.5	22
10	Strategies for validating biomarkers using data from a reference set. <i>Biostatistics</i> , 2021, 22, 298-314.	0.9	1
11	Hybrid design evaluating new biomarkers when there is an existing screening test. <i>Statistics in Medicine</i> , 2021, 40, 2037-2054.	0.8	0
12	International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2021, 160, 2572-2584.	0.6	91
13	Adding Rigor to Biomarker Evaluations"EDRN Experience. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2575-2582.	1.1	24
14	Ultra-Short Circulating Tumor DNA (usctDNA) in Plasma and Saliva of Non-Small Cell Lung Cancer (NSCLC) Patients. <i>Cancers</i> , 2020, 12, 2041.	1.7	28
15	DNA methylation and cis-regulation of gene expression by prostate cancer risk SNPs. <i>PLoS Genetics</i> , 2020, 16, e1008667.	1.5	15
16	Copy number alterations are associated with metastatic-lethal progression in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 494-506.	2.0	12
17	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 372-379.	3.0	79
18	A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. <i>Prostate</i> , 2019, 79, 1589-1596.	1.2	8

#	ARTICLE	IF	CITATIONS
19	Validation of a novel model for the early detection of hepatocellular carcinoma. <i>Clinical Proteomics</i> , 2019, 16, 2.	1.1	21
20	Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 530-532.	0.2	27
21	Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. <i>European Urology Focus</i> , 2019, 5, 54-61.	1.6	18
22	Model-free Scoring System for Risk Prediction with Application to Hepatocellular Carcinoma Study. <i>Biometrics</i> , 2018, 74, 239-248.	0.8	3
23	Combining multiple biomarkers linearly to maximize the partial area under the ROC curve. <i>Statistics in Medicine</i> , 2018, 37, 627-642.	0.8	21
24	A Prospective Study to Establish a New-Onset Diabetes Cohort. <i>Pancreas</i> , 2018, 47, 1244-1248.	0.5	62
25	Standard Operating Procedures for Biospecimen Collection, Processing, and Storage. <i>Pancreas</i> , 2018, 47, 1213-1221.	0.5	22
26	PROspective Evaluation of Chronic Pancreatitis for EpidEmiologic and Translational StuDies. <i>Pancreas</i> , 2018, 47, 1229-1238.	0.5	67
27	A fiveâ€CpG DNA methylation score to predict metastaticâ€Clethal outcomes in men treated with radical prostatectomy for localized prostate cancer. <i>Prostate</i> , 2018, 78, 1084-1091.	1.2	16
28	Model to Determine Risk of Pancreatic Cancer in Patients With New-Onset Diabetes. <i>Gastroenterology</i> , 2018, 155, 730-739.e3.	0.6	215
29	Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 311-319.	3.2	65
30	Gene expression panel predicts metastaticâ€Clethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. <i>Molecular Oncology</i> , 2017, 11, 140-150.	2.1	24
31	A Community-Based Randomized Trial of Hepatitis B Screening Among High-Risk Vietnamese Americans. <i>American Journal of Public Health</i> , 2017, 107, 433-440.	1.5	18
32	Association Between Combined <i>TMPRSS2:ERG</i> and <i>PCA3</i> RNA Urinary Testing and Detection of Aggressive Prostate Cancer. <i>JAMA Oncology</i> , 2017, 3, 1085.	3.4	120
33	Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw266.	3.0	116
34	Estimation of smooth ROC curves for biomarkers with limits of detection. <i>Statistics in Medicine</i> , 2017, 36, 3830-3843.	0.8	6
35	Addressing multilevel barriers to cervical cancer screening in Korean American women: A randomized trial of a communityâ€Cbased intervention. <i>Cancer</i> , 2017, 123, 1018-1026.	2.0	32
36	<i>PTEN</i> loss is associated with prostate cancer recurrence and alterations in tumor DNA methylation profiles. <i>Oncotarget</i> , 2017, 8, 84338-84348.	0.8	32

#	ARTICLE	IF	CITATIONS
37	A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. PLoS ONE, 2016, 11, e0167070.	1.1	24
38	Loss of Expression of AZGP1 Is Associated With Worse Clinical Outcomes in a Multi-Institutional Radical Prostatectomy Cohort. Prostate, 2016, 76, 1409-1419.	1.2	19
39	Comparison of two correlated ROC curves at a given specificity or sensitivity level. Statistics in Medicine, 2016, 35, 4352-4367.	0.8	13
40	Unbiased Estimation of Biomarker Panel Performance When Combining Training and Testing Data in a Group Sequential Design. Biometrics, 2016, 72, 888-896.	0.8	4
41	Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clinical Epigenetics, 2016, 8, 97.	1.8	34
42	Histologic Grading of Prostatic Adenocarcinoma Can Be Further Optimized. American Journal of Surgical Pathology, 2016, 40, 1439-1456.	2.1	107
43	Analytic validation of a clinical-grade PTEN immunohistochemistry assay in prostate cancer by comparison with PTEN FISH. Modern Pathology, 2016, 29, 904-914.	2.9	71
44	Evaluation of a novel saliva-based epidermal growth factor receptor mutation detection for lung cancer: A pilot study. Thoracic Cancer, 2016, 7, 428-436.	0.8	64
45	Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence. Statistics in Medicine, 2016, 35, 1267-1280.	0.8	4
46	A two-stage approach for dynamic prediction of time-to-event distributions. Statistics in Medicine, 2016, 35, 2167-2182.	0.8	17
47	PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer. European Urology Focus, 2016, 2, 180-188.	1.6	60
48	Early-Phase Studies of Biomarkers: What Target Sensitivity and Specificity Values Might Confer Clinical Utility?. Clinical Chemistry, 2016, 62, 737-742.	1.5	61
49	Serum Glycans as Risk Markers for Non-Small Cell Lung Cancer. Cancer Prevention Research, 2016, 9, 317-323.	0.7	15
50	Salivary Biomarkers for Detection of Oral Squamous Cell Carcinoma in a Taiwanese Population. Clinical Cancer Research, 2016, 22, 3340-3347.	3.2	62
51	Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort. Journal of Urology, 2016, 195, 313-320.	0.2	122
52	MUC1 Expression by Immunohistochemistry Is Associated with Adverse Pathologic Features in Prostate Cancer: A Multi-Institutional Study. PLoS ONE, 2016, 11, e0165236.	1.1	19
53	Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients. PLoS ONE, 2015, 10, e0132343.	1.1	28
54	Improving the Quality of Biomarker Discovery Research: The Right Samples and Enough of Them. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 944-950.	1.1	41

#	ARTICLE	IF	CITATIONS
55	A multicenter study shows <i>PTEN</i> deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer. <i>Prostate</i> , 2015, 75, 1206-1215.	1.2	55
56	Toward Rigorous Data Harmonization in Cancer Epidemiology Research: One Approach. <i>American Journal of Epidemiology</i> , 2015, 182, kww133.	1.6	30
57	Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 677-682.	1.1	17
58	Two-stage biomarker panel study and estimation allowing early termination for futility. <i>Biostatistics</i> , 2015, 16, 799-812.	0.9	2
59	MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. <i>Cancer Prevention Research</i> , 2015, 8, 1112-1119.	0.7	25
60	Associations of Body Mass Index, Smoking, and Alcohol Consumption With Prostate Cancer Mortality in the Asia Cohort Consortium. <i>American Journal of Epidemiology</i> , 2015, 182, 381-389.	1.6	42
61	Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B. <i>Journal of Clinical Oncology</i> , 2015, 33, 3880-3886.	0.8	88
62	Burden of Total and Cause-Specific Mortality Related to Tobacco Smoking among Adults Aged ≥ 45 Years in Asia: A Pooled Analysis of 21 Cohorts. <i>PLoS Medicine</i> , 2014, 11, e1001631.	3.9	98
63	Noninvasive Saliva-based <i>EGFR</i> Gene Mutation Detection in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1117-1126.	2.5	146
64	Validation Study of Genes with Hypermethylated Promoter Regions Associated with Prostate Cancer Recurrence. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1331-1339.	1.1	34
65	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	0.8	234
66	Methylation analysis in spontaneous sputum for lung cancer diagnosis. <i>Lung Cancer</i> , 2014, 84, 127-133.	0.9	27
67	Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study. <i>Clinical Cancer Research</i> , 2013, 19, 2442-2450.	3.2	132
68	The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1464-1469.	0.8	3
69	Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. <i>Cancer Epidemiology</i> , 2013, 37, 666-670.	0.8	30
70	The Impact of Prostate Volume, Number of Biopsy Cores and American Urological Association Symptom Score on the Sensitivity of Cancer Detection Using the Prostate Cancer Prevention Trial Risk Calculator. <i>Journal of Urology</i> , 2013, 190, 70-76.	0.2	38
71	The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers. <i>Clinical Chemistry</i> , 2013, 59, 68-74.	1.5	50
72	Meat intake and cause-specific mortality: a pooled analysis of Asian prospective cohort studies. <i>American Journal of Clinical Nutrition</i> , 2013, 98, 1032-1041.	2.2	109

#	ARTICLE	IF	CITATIONS
73	Association of body mass index and risk of death from pancreas cancer in Asians. <i>European Journal of Cancer Prevention</i> , 2013, 22, 244-250.	0.6	23
74	A Model for the Design and Construction of a Resource for the Validation of Prognostic Prostate Cancer Biomarkers. <i>Advances in Anatomic Pathology</i> , 2013, 20, 39-44.	2.4	24
75	Specific Glycoforms of MUC5AC and Endorepellin Accurately Distinguish Mucinous from Nonmucinous Pancreatic Cysts. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 2724-2734.	2.5	33
76	Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. <i>BMJ</i> , 2013, 347, f5446-f5446.	3.0	239
77	Proinflammatory Surfactant Protein B As a Biomarker for Lung Cancer Prediction. <i>Journal of Clinical Oncology</i> , 2013, 31, 4536-4543.	0.8	73
78	Logistic regression analysis with standardized markers. <i>Annals of Applied Statistics</i> , 2013, 7, .	0.5	6
79	LOGISTIC REGRESSION ANALYSIS WITH STANDARDIZED MARKERS. , 2013, 7, .		5
80	Biases Introduced by Choosing Controls to Match Risk Factors of Cases in Biomarker Research. <i>Clinical Chemistry</i> , 2012, 58, 1242-1251.	1.5	40
81	Increased Plasma Levels of the APC-Interacting Protein MAPRE1, LRG1, and IGFBP2 Preceding a Diagnosis of Colorectal Cancer in Women. <i>Cancer Prevention Research</i> , 2012, 5, 655-664.	0.7	77
82	Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera. <i>Cancer Prevention Research</i> , 2012, 5, 1036-1043.	0.7	57
83	Prevalidation of Salivary Biomarkers for Oral Cancer Detection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 664-672.	1.1	150
84	Identification of osteopontin as a novel marker for early hepatocellular carcinoma. <i>Hepatology</i> , 2012, 55, 483-490.	3.6	268
85	Updating risk prediction tools: A case study in prostate cancer. <i>Biometrical Journal</i> , 2012, 54, 127-142.	0.6	26
86	Enhanced Discrimination of Malignant from Benign Pancreatic Disease by Measuring the CA 19-9 Antigen on Specific Protein Carriers. <i>PLoS ONE</i> , 2011, 6, e29180.	1.1	61
87	Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score. <i>BJU International</i> , 2011, 107, 1562-1569.	1.3	36
88	Borrowing Information Across Populations in Estimating Positive and Negative Predictive Values. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2011, 60, 633-653.	0.5	5
89	Genetic Polymorphisms in Inflammation Pathway Genes and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 923-933.	1.1	54
90	Improving Biomarker Identification with Better Designs and Reporting. <i>Clinical Chemistry</i> , 2011, 57, 1093-1095.	1.5	28

#	ARTICLE	IF	CITATIONS
91	Ulcerative Colitis-associated Colorectal Cancer Arises in a Field of Short Telomeres, Senescence, and Inflammation. <i>Cancer Research</i> , 2011, 71, 1669-1679.	0.4	123
92	Genetic Variants in the <i>LEPR</i> , <i>CRY1</i> , <i>RNASEL</i> , <i>IL4</i> , and <i>ARVCF</i> Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1928-1936.	1.1	68
93	Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians. <i>New England Journal of Medicine</i> , 2011, 364, 719-729.	13.9	730
94	Body Mass Index and Diabetes in Asia: A Cross-Sectional Pooled Analysis of 900,000 Individuals in the Asia Cohort Consortium. <i>PLoS ONE</i> , 2011, 6, e19930.	1.1	154
95	Glycosylation Variants of Mucins and CEACAMs As Candidate Biomarkers for the Diagnosis of Pancreatic Cystic Neoplasms. <i>Annals of Surgery</i> , 2010, 251, 937-945.	2.1	83
96	Vitamin D pathway gene variants and prostate cancer prognosis. <i>Prostate</i> , 2010, 70, 1448-1460.	1.2	77
97	Re: Lung Cancer Risk Among Female Textile Workers Exposed to Endotoxin. <i>Journal of the National Cancer Institute</i> , 2010, 102, 913-914.	3.0	7
98	Use of Aspirin and Other Nonsteroidal Antiinflammatory Medications in Relation to Prostate Cancer Risk. <i>American Journal of Epidemiology</i> , 2010, 172, 578-590.	1.6	86
99	Boosting with missing predictors. <i>Biostatistics</i> , 2010, 11, 195-212.	0.9	5
100	Alpha-Fetoprotein in Early Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 138, 400-401.	0.6	13
101	Canary Prostate Active Surveillance Study: Design of a Multi-institutional Active Surveillance Cohort and Biorepository. <i>Urology</i> , 2010, 75, 407-413.	0.5	70
102	Classification versus association models: Should the same methods apply?. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2010, 70, 53-58.	0.6	18
103	A Multicenter, Double-Blinded Validation Study of Methylation Biomarkers for Progression Prediction in Barrett's Esophagus. <i>Cancer Research</i> , 2009, 69, 4112-4115.	0.4	202
104	Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. <i>Statistics in Medicine</i> , 2009, 28, 762-779.	0.8	33
105	Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. <i>Prostate</i> , 2009, 69, 363-372.	1.2	80
106	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2009, 137, 110-118.	0.6	644
107	Prostate Cancer Specific Mortality and Gleason 7 Disease Differences in Prostate Cancer Outcomes Between Cases With Gleason 4 + 3 and Gleason 3 + 4 Tumors in a Population Based Cohort. <i>Journal of Urology</i> , 2009, 182, 2702-2707.	0.2	133
108	Toward a Robust System for Biomarker Triage and Validation â€œ EDRN Experience. , 2009, , 297-306.		2

#	ARTICLE	IF	CITATIONS
109	Mediation of Adult Fruit and Vegetable Consumption in the National 5 A Day for Better Health Community Studies. <i>Annals of Behavioral Medicine</i> , 2008, 35, 49-60.	1.7	40
110	Occupational risk factors for endometrial cancer among textile workers in Shanghai, China. <i>American Journal of Industrial Medicine</i> , 2008, 51, 673-679.	1.0	20
111	Ulcerative Colitis Is a Disease of Accelerated Colon Aging: Evidence From Telomere Attrition and DNA Damage. <i>Gastroenterology</i> , 2008, 135, 410-418.	0.6	153
112	Application of Multidimensional Selective Item Response Regression Model for Studying Multiple Gene Methylation in SV40 Oncogenic Pathways. <i>Journal of the American Statistical Association</i> , 2008, 103, 201-211.	1.8	1
113	Occupational Exposures and Ovarian Cancer in Textile Workers. <i>Epidemiology</i> , 2008, 19, 244-250.	1.2	22
114	SELDI-TOF MS Whole Serum Proteomic Profiling with IMAC Surface Does Not Reliably Detect Prostate Cancer. <i>Clinical Chemistry</i> , 2008, 54, 53-60.	1.5	128
115	The Importance of Test Positive Predictive Value in Ovarian Cancer Screening. <i>Clinical Cancer Research</i> , 2008, 14, 7574-7574.	3.2	22
116	Multiple Independent Genetic Variants in the 8q24 Region Are Associated with Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1203-1213.	1.1	67
117	Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias. <i>Clinical Chemistry</i> , 2008, 54, 44-52.	1.5	126
118	Occurrence of Autoantibodies to Annexin I, 14-3-3 Theta and LAMR1 in Prediagnostic Lung Cancer Sera. <i>Journal of Clinical Oncology</i> , 2008, 26, 5060-5066.	0.8	178
119	Pivotal Evaluation of the Accuracy of a Biomarker Used for Classification or Prediction: Standards for Study Design. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1432-1438.	3.0	597
120	Diagnostic Markers for Early Detection of Ovarian Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1065-1072.	3.2	371
121	Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features. <i>PLoS ONE</i> , 2008, 3, e1890.	1.1	76
122	Occupational Exposures and Breast Cancer Among Women Textile Workers in Shanghai. <i>Epidemiology</i> , 2007, 18, 383-392.	1.2	31
123	Integrating the Predictiveness of a Marker with Its Performance as a Classifier. <i>American Journal of Epidemiology</i> , 2007, 167, 362-368.	1.6	236
124	Lung Cancer Risk Among Female Textile Workers Exposed to Endotoxin. <i>Journal of the National Cancer Institute</i> , 2007, 99, 357-364.	3.0	76
125	A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy. <i>Clinical Cancer Research</i> , 2007, 13, 6984-6992.	3.2	69
126	Application of a methylation gene panel by quantitative PCR for lung cancers. <i>Cancer Letters</i> , 2007, 247, 56-71.	3.2	87

#	ARTICLE	IF	CITATIONS
127	Polymorphisms, Mutations, and Amplification of the EGFR Gene in Non-Small Cell Lung Cancers. <i>PLoS Medicine</i> , 2007, 4, e125.	3.9	130
128	Evaluating the Predictiveness of a Continuous Marker. <i>Biometrics</i> , 2007, 63, 1181-1188.	0.8	102
129	Telomere Length in the Colon Declines with Age: a Relation to Colorectal Cancer?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 573-577.	1.1	73
130	Modeling, Estimation and Validation of Cotton Dust and Endotoxin Exposures in Chinese Textile Operations. <i>Annals of Occupational Hygiene</i> , 2006, 50, 573-82.	1.9	34
131	Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. <i>Journal of the National Cancer Institute</i> , 2006, 98, 529-534.	3.0	851
132	Application of the Time-Dependent ROC Curves for Prognostic Accuracy with Multiple Biomarkers. <i>Biometrics</i> , 2006, 62, 279-287.	0.8	66
133	Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. <i>Oncogene</i> , 2005, 24, 732-736.	2.6	54
134	Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. <i>Oncogene</i> , 2005, 24, 4138-4148.	2.6	240
135	Optimized Normalization for Antibody Microarrays and Application to Serum-Protein Profiling. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 773-784.	2.5	102
136	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. <i>Clinical Chemistry</i> , 2005, 51, 102-112.	1.5	336
137	Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers. <i>Journal of the National Cancer Institute</i> , 2005, 97, 339-346.	3.0	2,194
138	Antibody Microarray Profiling Reveals Individual and Combined Serum Proteins Associated with Pancreatic Cancer. <i>Cancer Research</i> , 2005, 65, 11193-11202.	0.4	141
139	Quantifying Peptide Signal in MALDI-TOF Mass Spectrometry Data. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1990-1999.	2.5	25
140	Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials. <i>Contemporary Clinical Trials</i> , 2005, 26, 45-58.	0.8	38
141	Profiling High-Dimensional Protein Expression Using MALDI-TOF. , 2005, , 437-456.		1
142	Statistical Considerations in Combining Biomarkers for Disease Classification. <i>Disease Markers</i> , 2004, 20, 45-51.	0.6	12
143	Serum Protein Expression Profiling for Cancer Detection: Validation of a SELDI-Based Approach for Prostate Cancer. <i>Disease Markers</i> , 2004, 19, 185-195.	0.6	57
144	Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. <i>Pharmacogenomics</i> , 2004, 5, 709-719.	0.6	115

#	ARTICLE	IF	CITATIONS
145	DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. <i>Clinical Cancer Research</i> , 2004, 10, 2928-2935.	3.2	59
146	Presence of Simian Virus 40 DNA Sequences in Human Lymphoid and Hematopoietic Malignancies and Their Relationship to Aberrant Promoter Methylation of Multiple Genes. <i>Cancer Research</i> , 2004, 64, 3757-3760.	0.4	53
147	Partially Supervised Learning Using an EM Boosting Algorithm. <i>Biometrics</i> , 2004, 60, 199-206.	0.8	14
148	Evaluation of Community-Intervention Trials via Generalized Linear Mixed Models. <i>Biometrics</i> , 2004, 60, 1043-1052.	0.8	10
149	Vitamin D receptor gene polymorphisms and prostate cancer risk. <i>Prostate</i> , 2004, 59, 409-418.	1.2	61
150	The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2004, 22, 337-343.	0.8	45
151	Small Sample Inference for Clustered Data. <i>Lecture Notes in Statistics</i> , 2004, , 71-87.	0.1	2
152	Identifying settings when permutation tests have nominal size with paired, binary-outcome, group randomized trials. <i>Journal of Nonparametric Statistics</i> , 2003, 15, 653-663.	0.4	1
153	A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. <i>Biostatistics</i> , 2003, 4, 449-463.	0.9	254
154	An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. <i>Journal of Biomedicine and Biotechnology</i> , 2003, 2003, 242-248.	3.0	103
155	Presence of simian virus 40 DNA sequences in human lymphomas. <i>Lancet, The</i> , 2002, 359, 851-852.	6.3	142
156	Boosted Decision Tree Analysis of Surface-enhanced Laser Desorption/Ionization Mass Spectral Serum Profiles Discriminates Prostate Cancer from Noncancer Patients. <i>Clinical Chemistry</i> , 2002, 48, 1835-1843.	1.5	414
157	Some design issues in a community intervention trial. <i>Contemporary Clinical Trials</i> , 2002, 23, 431-449.	2.0	28
158	Cancer prevention behaviors and socioeconomic status among Hispanics and non-Hispanic whites in a rural population in the United States. <i>Cancer Causes and Control</i> , 2002, 13, 719-728.	0.8	61
159	Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. <i>Cancer Research</i> , 2002, 62, 3609-14.	0.4	630
160	Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. <i>Clinical Chemistry</i> , 2002, 48, 1835-43.	1.5	103
161	Seattle 5 a Day Worksite Program to Increase Fruit and Vegetable Consumption. <i>Preventive Medicine</i> , 2001, 32, 230-238.	1.6	150
162	Optimal Permutation Tests for the Analysis of Group Randomized Trials. <i>Journal of the American Statistical Association</i> , 2001, 96, 1424-1432.	1.8	61

#	ARTICLE	IF	CITATIONS
163	Phases of Biomarker Development for Early Detection of Cancer. Journal of the National Cancer Institute, 2001, 93, 1054-1061.	3.0	1,431
164	A comparison of generalized linear mixed model procedures with estimating equations for variance and covariance parameter estimation in longitudinal studies and group randomized trials. Statistics in Medicine, 2001, 20, 3353-3373.	0.8	31
165	Selected Statistical Issues in Group Randomized Trials. Annual Review of Public Health, 2001, 22, 167-187.	7.6	134
166	Baseline Fruit and Vegetable Intake among Adults in Seven 5 A Day Study Centers Located in Diverse Geographic Areas. Journal of the American Dietetic Association, 1999, 99, 1241-1248.	1.3	128
167	Explaining community-level variance in group randomized trials. , 1999, 18, 539-556.		30
168	Impact of Work Site Health Promotion on Stages of Dietary Change: The Working Well Trial. Health Education and Behavior, 1998, 25, 448-463.	1.3	73
169	A COMPARISON OF STATISTICAL METHODS FOR CLUSTERED DATA ANALYSIS WITH GAUSSIAN ERROR. , 1996, 15, 1793-1806.		132
170	Correlated binomial variates: Properties of estimator of intraclass correlation and its effect on sample size calculation. Statistics in Medicine, 1992, 11, 1607-1614.	0.8	62